89P Novel resistance mechanisms to second-generation EGFR tyrosine kinase inhibitor afatinib in non-small cell lung cancer

Abstract

Afatinib, an irreversible pan-ErbB family inhibitor, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) patients with uncommon EGFR activating mutations. However, besides the acquisition of secondary T790M mutation, other resistance mechanisms to afatinib remained to be explored.